The FDA approval introduces a nonprescription fixed-dose combination of 2 widely used analgesics for temporary relief of common minor aches and pains in adults and children aged 12 years or older.
The FDA expanded approval of exagamglogene autotemcel (Casgevy) for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent β-thalassemia.
...
A systematic review and meta-analysis published in Archives of Dermatological Research quantifies the prevalence of sleep disturbances among patients with atopic dermatitis, highlighting substantial disease...
In two pragmatic randomized trials conducted in the Capital Region of Denmark, investigators compared collaborative care with consultation liaison in general practice to assess whether greater involvement...
A randomized clinical trial evaluating 2 types of 1-page educational resources for low back pain found that fact sheets listing treatment options modestly improved patients’ preparedness for shared...
The FDA has approved veligrotug-vvze (Lumvoa) for the treatment of thyroid eye disease regardless of disease activity or duration, based on the pivotal phase 3 THRIVE and THRIVE-2 clinical trials.
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
The FDA approved tebipenem pivoxil (Utebzi) for adults with complicated urinary tract infections, including pyelonephritis, who have limited or no alternative oral treatment options.
In an international Bayesian adaptive RCT of adults with MSSA bacteremia, cefazolin was noninferior to flucloxacillin or cloxacillin for 90-day all-cause mortality and was associated with less acute kidney...
Using real-world patient scenarios and current guideline recommendations, this session from Practical Updates in Primary Care outlines a structured primary care approach to diagnosing low back pain,...
